PDF(Pubmed)
Abstract：
Histone alterations are a hallmark of kidney cancer. Histone acetylation modification mediated by bromodomain proteins (BRD) has been indicated to be related to a variety of cancer types and several targeted inhibitors have been proven to be promising modalities for cancer adjuvant therapy. As renal cell carcinoma (RCC) is not sensitive to radiotherapy or chemotherapy, the exploration of effective adjuvant therapies remains an important research direction for advanced RCC. At present, studies on bromodomain family proteins in RCC are limited and the roles of bromodomain family proteins in RCC have remained to be fully elucidated. The present review discussed the role of bromodomain family proteins in RCC, aiming to explore possible potential therapeutic targets of BRD‑related drugs in this type of cancer.
摘要：
组蛋白改变是肾癌的标志。由溴结构域蛋白（BRD）介导的组蛋白乙酰化修饰已被表明与多种癌症类型有关，并且几种靶向抑制剂已被证明是癌症辅助治疗的有希望的方式。由于肾细胞癌（RCC）对放疗或化疗不敏感，探索有效的辅助治疗仍是晚期肾癌的重要研究方向。目前,关于溴结构域家族蛋白在RCC中的研究有限，溴结构域家族蛋白在RCC中的作用仍有待充分阐明。本文综述了溴结构域家族蛋白在肾癌中的作用。旨在探索BRD相关药物在此类癌症中可能的潜在治疗靶点。
